tazobactam has been researched along with nxl 104 in 3 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (nxl 104) | Trials (nxl 104) | Recent Studies (post-2010) (nxl 104) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 7 | 0 | 5 |
| Protein | Taxonomy | tazobactam (IC50) | nxl 104 (IC50) |
|---|---|---|---|
| Peptidoglycan D,D-transpeptidase MrdA | Escherichia coli K-12 | 0.59 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barraja, P; Carbone, A; Cascioferro, S; Cirrincione, G; Diana, P; Montalbano, A; Parrino, B; Schillaci, D; Spanò, V | 1 |
| Martin, NI; Tehrani, KHME | 1 |
| Colchón, E; González-Bello, C; Pernas, M; Rodríguez, Á; Rodríguez, D | 1 |
2 review(s) available for tazobactam and nxl 104
| Article | Year |
|---|---|
β-lactam/β-lactamase inhibitor combinations: an update.
Topics: | 2018 |
β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactamases; Drug Resistance, Microbial; Humans; Protein Structure, Secondary; Protein Structure, Tertiary; Treatment Outcome | 2020 |
1 other study(ies) available for tazobactam and nxl 104
| Article | Year |
|---|---|
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Drug Resistance, Microbial; Enterobacteriaceae Infections; Humans; Imipenem; Pseudomonas Infections | 2017 |